Search results for "Keratan Sulfate"

showing 7 items of 7 documents

Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study.

2017

Efficacy and safety of elosulfase alfa enzyme replacement therapy (ERT) were assessed in an open-label, phase 2, multi-national study in Morquio A patients aged ≥5 years unable to walk ≥30 meters in the 6-min walk test. Patients received elosulfase alfa 2.0 mg/kg/week intravenously for 48 weeks. Efficacy measures were functional dexterity, pinch/grip strength, mobility in a modified timed 25-foot walk, pain, quality of life, respiratory function, and urine keratan sulfate (KS). Safety/tolerability was also assessed. Fifteen patients received elosulfase alfa, three patients discontinued ERT due to adverse events (two were grade 3 drug-related adverse events, the other was not drug-related), …

0301 basic medicineMaleWalkingchemistry.chemical_compoundGrip strengthGALNS protein0302 clinical medicineElosulfase alfaQuality of lifeActivities of Daily LivingRespiratory functionFunctional abilityChildGenetics (clinical)education.field_of_studyMucopolysaccharidosis IVChondroitinsulfatases3. Good healthRespiratory Function TestsTreatment OutcomeTolerability6.1 PharmaceuticalsOriginal ArticleFemalePatient Safetyphysical enduranceGALNS protein human [supplementary concept]Adultsafetymedicine.medical_specialtyAdolescentClinical Trials and Supportive ActivitiesPopulationClinical Sciences03 medical and health sciencesYoung Adultmobility limitationClinical ResearchInternal medicinemedicineGeneticsHumansEnzyme Replacement TherapyAdverse effecteducationhuman [supplementary concept]Exercisebusiness.industryEvaluation of treatments and therapeutic interventionsOriginal Articles030104 developmental biologychemistryKeratan SulfateQuality of LifeSelf Reportbusiness030217 neurology & neurosurgeryBiomarkers
researchProduct

Extracellular matrix composition in COPD

2012

Extracellular matrix (ECM) composition has an important role in determining airway structure. We postulated that ECM lung composition of chronic obstructive pulmonary disease (COPD) patients differs from that observed in smoking and nonsmoking subjects without airflow obstruction. We determined the fractional areas of elastic fibres, type-I, -III and -IV collagen, versican, decorin, biglycan, lumican, fibronectin and tenascin in different compartments of the large and small airways and lung parenchyma in 26 COPD patients, 26 smokers without COPD and 16 nonsmoking control subjects. The fractional area of elastic fibres was higher in non-obstructed smokers than in COPD and nonsmoking controls…

AdultMalePulmonary and Respiratory MedicineLumicanPathologymedicine.medical_specialtyDecorinLumicanTenascinSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease Chronic ObstructiveBiglycanParenchymamedicineHumansCOPDLungAgedCOPDLungbiologybusiness.industryBiglycanSmokingTenascinMiddle Agedrespiratory systemmedicine.diseaseImmunohistochemistryExtracellular MatrixFibronectinsRespiratory Function Testsrespiratory tract diseasesmedicine.anatomical_structureChondroitin Sulfate ProteoglycansKeratan SulfateCase-Control Studiesbiology.proteinVersicanFemaleCollagenDecorinbusiness
researchProduct

The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects

2013

Abstract Objectives The objectives of this study are to quantify endurance and respiratory function and better characterize spectrum of symptoms and biochemical abnormalities in mucopolysaccharidosis IVA subjects. Methods MorCAP was a multicenter, multinational, cross sectional study amended to be longitudinal in 2011. Each study visit required collection of medical history, clinical assessments, and keratan sulfate (KS) levels. Results Data from the first visit of 325 subjects (53% female) were available. Mean age was 14.5 years. Mean ± SD height z-scores were − 5.6 ± 3.1 as determined by the CDC growth charts. Mean ± SD from the 6-minute-walk-test was 212.6 ± 152.2 m, revealing limitation…

AdultMaleVital capacitymedicine.medical_specialtyAdolescentCross-sectional studyEndocrinology Diabetes and MetabolismMucopolysaccharidosisMotor ActivityBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyElosulfase alfaQuality of lifeSurveys and QuestionnairesInternal medicineActivities of Daily LivingGeneticsmedicineHumansMedical historyRespiratory functionChildExerciseMolecular BiologyGlycosaminoglycans030304 developmental biology0303 health sciencesbusiness.industryInfant NewbornInfantMucopolysaccharidosis IVmedicine.diseaseUnited StatesRespiratory Function TestsCross-Sectional StudieschemistryKeratan SulfateChild PreschoolPhysical EnduranceQuality of LifeMucopolysaccharidosis IVPhysical therapyFemalebusiness030217 neurology & neurosurgeryMolecular Genetics and Metabolism
researchProduct

Development and testing of new screening method for keratan sulfate in mucopolysaccharidosis IVA.

2004

Mucopolysaccharidosis IVA (MPS IVA), a progressive lysosomal storage disease, causes skeletal dysplasia through excessive storage of keratan sulfate (KS). We developed an ELISA-sandwich assay that used a MAb specific to KS. Forty-five blood and 59 urine specimens from MPS IVA patients (ages 1–65 y) were analyzed to determine whether KS concentration is a suitable marker for early diagnosis and longitudinal assessment of disease severity. Blood specimens were obtained from patients categorized as phenotypically severe (n = 36) and milder (n = 9). Urine specimens were also analyzed from patients categorized as severe (n = 56) and milder (n = 12), respectively. Blood KS levels (101–1525 ng/mL)…

Adultmedicine.medical_specialtyPathologyAdolescentMucopolysaccharidosisStatistics as TopicEnzyme-Linked Immunosorbent AssayUrineGastroenterologyMucopolysaccharidosis Type IVAExcretionDiagnosis Differentialchemistry.chemical_compoundInternal medicinemedicineLysosomal storage diseaseHumansGenetic TestingChildAgedGlycosaminoglycansCreatininebusiness.industryInfantMucopolysaccharidosis IVReproducibility of ResultsMiddle Agedmedicine.diseasechemistryDysplasiaKeratan SulfateChild PreschoolPediatrics Perinatology and Child HealthMucopolysaccharidosis IVsense organsbusinessBiomarkersPediatric research
researchProduct

Fetal presentation of Morquio disease type A.

1992

A fetus with mucopolysaccharidosis type IV A (Morquio type A) is described. The family had one affected child exhibiting symptoms of classical Morquio A disease, and late in the subsequent pregnancy prenatal diagnosis was requested. At 23 weeks' gestation, moderate ascites was detected by detailed ultrasound scan and keratan sulphate was found in the amniotic fluid. The pregnancy was terminated by prostaglandin induction and the diagnosis of mucopolysaccharidosis type IV A was confirmed by demonstration of a deficiency of N-acetylgalactosamine-6-sulphate (GalNac-6-S) sulphatase in cultured amniotic cells and in post-mortem fibroblast cultures. The activities of beta-galactosidase and arylsu…

ElectrophoresisMalemedicine.medical_specialtyAmniotic fluidPlacentaMucopolysaccharidosis type IVNeuraminidasePrenatal diagnosisConsanguinityPregnancyHydrops fetalisInternal medicineLysosomal storage diseaseMedicineHumansChildGenetics (clinical)GlycosaminoglycansUltrasonographyFetusPregnancybusiness.industryObstetrics and GynecologyAscitesMucopolysaccharidosis IVmedicine.diseaseAmniotic Fluidbeta-GalactosidaseEndocrinologyKeratan SulfatePregnancy Trimester SecondMucopolysaccharidosis IVAmniocentesisFemaleSulfatasesbusinessPrenatal diagnosis
researchProduct

The mucopolysaccharidoses: Inborn errors of glycosaminoglycan catabolism

1976

The mucopolysaccharidoses are genetic disorders of glycosaminoglycan metabolism. Patients with these diseases accumulate within the lysosomes of most tissues excessive amounts of dermatan and/or heparan sulfates, or of keratan sulfate. The clinical consequences of such glycosaminoglycan storage range from skeletal abnormalities to cardiovascular problems, and to motor and mental retardation. In all mucopolysaccharidoses, except Morquio disease, an excessive accumulation of sulfate-labeled glycosaminoglycans has been demonstrated in fibroblasts cultured from the patient's skin. It was subsequently shown that this was due to the deficiency of specific proteins which were named "corrective fac…

Glycoside HydrolasesKeratan sulfateMucopolysaccharidosisPrenatal diagnosisDiseaseMucopolysaccharidosesBiologyBioinformaticsmedicine.diseaseHuman geneticsEnzyme assayGlycosaminoglycanTissue culturechemistry.chemical_compoundPhenotypechemistryGeneticsmedicinebiology.proteinHumansSulfatasesLysosomesGenetics (clinical)GlycosaminoglycansHuman Genetics
researchProduct

Proteoglycan occurrence in gastrolith of the crayfish Cherax quadricarinatus (Malacostraca: Decapoda).

2012

14 pages; International audience; Biomineralized structures are hybrid composites formed and stabilized by the close interaction of the organic and the inorganic phases. Crayfish are good models for studying biomineralization because they develop, in a molting-mineralization cycle, semi-spherical mineralized structures referred to as gastroliths. The organic matrix of these structures consists of proteins, polysaccharides, and lipids. Chitin is the main polysaccharide and is concentrically arranged as fibrous chitin-protein lamellar structures. Although several proteins and low-molecular weight phosphorylated components have been reported to be involved in gastrolith mineralization, the occ…

Keratan sulfateCheraxAnatomyAquatic ScienceBiologyMatrix (biology)biology.organism_classificationbiomineralization[ SDV.IB.BIO ] Life Sciences [q-bio]/Bioengineering/BiomaterialsMolting cycleAmorphous calcium carbonatecarbohydrates (lipids)chemistry.chemical_compoundBiochemistrychemistryGastrolithProteoglycanglycosaminoglycansCherax quadricarinatusamorphous calcium carbonategastrolithbiology.proteinproteoglycanscalcium storageBiomineralization
researchProduct